Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients

• Published in: Mayo Clinic proceedings. Innovations, quality & outcomes quality & outcomes, 2022-04, Vol.6 (2), p.120-125
• Main Authors: Chumsri, Saranya, Advani, Pooja P., Pai, Tanmayi S., Li, Zhuo, Mummareddy, Ashita, Acampora, Marites, Reynolds, Gina A., Wylie, Natasha, Boyle, Ashton W., Lou, Yanyan, Mody, Kabir, Moreno-Aspitia, Alvaro, Swift, Melanie D., Virk, Abinash, Bharucha, Adil E., Marquez, Christopher P., Patel, Tushar C., Gores, Gregory J., Knutson, Keith L.
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2542-4548; 2542-4548
• DOI: 10.1016/j.mayocpiqo.2021.12.004

To evaluate the magnitude of humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with cancer receiving active therapies. Patients 18 years or older in whom SARS-CoV-2 spike antibody (anti-S Ab) levels were measured after 2 doses of SARS-CoV-2 mRNA vaccines were included. Patients with prior coronavirus disease 2019 (COVID-19) infection or receiving other immunosuppressive therapy were excluded. Among 201 patients who met the criteria, 61 were immunocompetent, 91 had a hematologic malignancy, and 49 had a solid malignancy while receiving treatments associated with cytopenia, including chemotherapy or cyclin-dependent kinase 4 and 6 inhibitors. A significantly greater proportion of immunocompetent patients (96.7% [59 of 61]) had anti-S Ab titers of 500 U/mL or greater compared to patients with hematologic (7.7% [7 of 91) and solid (55.1% [27 of 49]) malignancy (P